NEW YORK (360Dx) – BioReference Laboratories' GenPath Oncology Diagnostics division will participate in the National Cancer Institute's Molecular Analysis for Therapy Choice (NCI-MATCH) trial.
BioReference Labs signed a collaboration agreement with the National Cancer Institute and ECOG-ACRIN Cancer Research Group, which is coordinating the trial, BioReference parent company Opko Health announced today.